Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial

The Lancet

Volumn 388, Issue 10051, 2016, Pages 1281-1290

  Panés, Julián ^a   García Olmo, Damián ^b   Van Assche, Gert ^c   Colombel, Jean Frederic ^d   Reinisch, Walter ^e,f   Baumgart, Daniel C ^g   Dignass, Axel ^h   Nachury, Maria ⁱ   Ferrante, Marc ^c   Kazemi Shirazi, Lili ^e   Grimaud, Jean C ^j   de la Portilla, Fernando ^k   Goldin, Eran ^l   Richard, Marie Paule ^m   Leselbaum, Anne ^m   Danese, Silvio ⁿ  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f MCMASTER UNIVERSITY   (Canada)

^g HUMBOLDT UNIVERSITY   (Germany)

^h AGAPLESION MARKUS KRANKENHAUS   (Germany)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j HÔPITAL NORD   (France)

^k HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^l SHAARE ZEDEK MEDICAL CENTER   (Israel)

^m Parque Tecnologico de Madrid   (Spain)

ⁿ HUMANITAS UNIVERSITY   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR;

ABSCESS; ADIPOSE DERIVED MESENCHYMAL STEM CELL TRANSPLANTATION; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANAL ABSCESS; ANUS DISEASE; ANUS FISTULA; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROHN DISEASE; DOUBLE BLIND PROCEDURE; EUROPE; FEMALE; FOLLOW UP; GASTROENTEROLOGIST; HOSPITAL; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SAFETY; PRIORITY JOURNAL; PROCTALGIA; RADIOLOGIST; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; RHINOPHARYNGITIS; STEM CELL EXPANSION; THERAPY EFFECT; ADIPOSE TISSUE; AGED; ALLOTRANSPLANTATION; CLINICAL TRIAL; COMPLICATION; EVIDENCE BASED MEDICINE; MESENCHYMAL STROMA CELL; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RECTAL FISTULA; TREATMENT OUTCOME;

ADIPOSE TISSUE; ADULT; AGED; COMBINED MODALITY THERAPY; CROHN DISEASE; DOUBLE-BLIND METHOD; EUROPE; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; ISRAEL; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; RECTAL FISTULA; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84979752747     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31203-X     Document Type: Article

References (37)

1. 1 Baumgart, DC, Sandborn, WJ, Crohn's disease. Lancet 380 (2012), 1590–1605.
2. 2 Molodecky, NA, Soon, IS, Rabi, DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142 (2012), 46–54.
3. 3 Schwartz, DA, Loftus, EV Jr, Tremaine, WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 122 (2002), 875–880.
4. 4 Eglinton, TW, Barclay, ML, Gearry, RB, Frizelle, FA, The spectrum of perianal Crohn's disease in a population-based cohort. Dis Colon Rectum 55 (2012), 773–777.
5. 5 Hellers, G, Bergstrand, O, Ewerth, S, Holmstrom, B, Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut 21 (1980), 525–527.
6. 6 Scharl, M, Rogler, G, Pathophysiology of fistula formation in Crohn's disease. World J Gastrointest Pathophysiol 5 (2014), 205–212.
7. 7 Bell, SJ, Williams, AB, Wiesel, P, Wilkinson, K, Cohen, RC, Kamm, MA, The clinical course of fistulating Crohn's disease. Aliment Pharmacol Ther 17 (2003), 1145–1151.
8. 8 Sands, BE, Anderson, FH, Bernstein, CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004), 876–885.
9. 9 Thia, KT, Mahadevan, U, Feagan, BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 15 (2009), 17–24.
10. 10 Present, DH, Korelitz, BI, Wisch, N, Glass, JL, Sachar, DB, Pasternack, BS, Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 302 (1980), 981–987.
11. 11 Pearson, DC, May, GR, Fick, GH, Sutherland, LR, Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 123 (1995), 132–142.
12. 12 Present, DH, Rutgeerts, P, Targan, S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999), 1398–1405.
13. 13 Domenech, E, Hinojosa, J, Nos, P, et al. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?. Aliment Pharmacol Ther 22 (2005), 1107–1113.
14. 14 Goldstein, ES, Marion, JF, Present, DH, 6-mercaptopurine is effective in Crohn's disease without concomitant steroids. Inflamm Bowel Dis 10 (2004), 79–84.
15. 15 Korelitz, BI, Present, DH, Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease. Dig Dis Sci 30 (1985), 58–64.
16. 16 Brandt, LJ, Bernstein, LH, Boley, SJ, Frank, MS, Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 83 (1982), 383–387.
17. 17 Solomon, MJ, McLeod, RS, O'Connor, BI, et al. Combination ciprofloxacin and metronidazole in severe perianal Crohn's disease. Can J Gastroenterol 7 (1993), 571–573.
18. 18 Molendijk, I, Nuij, VJ, van der Meulen-de Jong, AE, van der Woude, CJ, Disappointing durable remission rates in complex Crohn's disease fistula. Inflamm Bowel Dis 20 (2014), 2022–2028.
19. 19 Gecse, K, Khanna, R, Stoker, J, et al. Fistulizing Crohn's disease: diagnosis and management. United European Gastroenterol J 1 (2013), 206–213.
20. 20 Singer, NG, Caplan, AI, Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol 6 (2011), 457–478.
21. 21 DelaRosa, O, Dalemans, W, Lombardo, E, Mesenchymal stem cells as therapeutic agents of inflammatory and autoimmune diseases. Curr Opin Biotechnol 23 (2012), 978–983.
22. 22 Garcia-Olmo, D, Guadalajara, H, Rubio-Perez, I, Herreros, MD, De La Quintana, P, Garcia-Arranz, M, Recurrent anal fistulae: limited surgery supported by stem cells. World J Gastroenterol 21 (2015), 3330–3336.
23. 23 de la Portilla, F, Alba, F, Garcia-Olmo, D, Herrerias, JM, Gonzalez, FX, Galindo, A, Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis 28 (2013), 313–323.
24. 24 Best, WR, Becktel, JM, Singleton, JW, Kern, F Jr, Development of a Crohn's Disease Activity Index. National Cooperative Crohn's Disease Study. Gastroenterology 70 (1976), 439–444.
25. 25 Kamm, MA, Ng, SC, Perianal fistulizing Crohn's disease: a call to action. Clin Gastroenterol Hepatol 6 (2008), 7–10.
26. 26 Irvine, EJ, Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 20 (1995), 27–32.
27. 27 Guyatt, G, Mitchell, A, Irvine, EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 96 (1989), 804–810.
28. 28 Colombel, JF, Schwartz, DA, Sandborn, WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 58 (2009), 940–948.
29. 29 Losco, A, Vigano, C, Conte, D, Cesana, BM, Basilisco, G, Assessing the activity of perianal Crohn's disease: comparison of clinical indices and computer-assisted anal ultrasound. Inflamm Bowel Dis 15 (2009), 742–749.
30. 30 Cho, YB, Lee, WY, Park, KJ, Kim, M, Yoo, HW, Yu, CS, Autologous adipose tissue-derived stem cells for the treatment of Crohn's fistula: a phase I clinical study. Cell Transplant 22 (2013), 279–285.
31. 31 Lee, WY, Park, KJ, Cho, YB, et al. Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn's fistula. Stem Cells 31 (2013), 2575–2581.
32. 32 Van Assche, G, Dignass, A, Reinisch, W, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 4 (2010), 63–101.
33. 33 Molendijk, I, Bonsing, BA, Roelofs, H, et al. Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn's disease. Gastroenterology 149 (2015), 918–927.
34. 34 Schwartz, DA, Herdman, CR, Review article: the medical treatment of Crohn's perianal fistulas. Aliment Pharmacol Ther 19 (2004), 953–967.
35. 35 American Gastroenterological Association Clinical Practice Committee. American Gastroenterological Association medical position statement: perianal Crohn's disease. Gastroenterology 125 (2003), 1503–1507.
36. 36 Geltzeiler, CB, Wieghard, N, Tsikitis, VL, Recent developments in the surgical management of perianal fistula for Crohn's disease. Ann Gastroenterol 27 (2014), 320–330.
37. 37 Ghannam, S, Pene, J, Moquet-Torcy, G, Jorgensen, C, Yssel, H, Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 185 (2010), 302–312.